Report Overview

Indian Rheumatoid Arthritis Drugs market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Rheumatoid arthritis is an inflammatory disease that results to cause pain and swelling in and around the joints. It usually affects hands and feet but can also affect any joint in the body. Rheumatoid arthritis is an autoimmune condition because of the immune cells targeting healthy body tissues. Patients can have joint swelling, stiffness and pain due to destruction of cartilage tissues and bones. The exact cause of disease is still unknown. Rheumatoid arthritis has four stages of progression and stage 3 shows the severe form of the disease. Rheumatoid arthritis affects performance of daily activities, like household tasks and work, and also results in mortality.



Market Drivers

The rising prevalence of rheumatoid arthritis in India, introduction of new therapeutic agents and government support on high cost treatment products are some of the major factors driving the rheumatoid arthritis market.These therapeutic treatment stops inflammation, relieve symptoms, prevent joint and organ damages and decreases long term complications which attracts rheumatoid arthritis patients to opt for these treatments, which results in market growth.Rising government initiatives to give quality and affordable healthcare are anticipated to supplement development of India's market. In addition, India is considered as one of the top countries of infections in the world, increasing the requirement for rheumatoid arthritis treatment around the country. Rising patient pool because of increase in population, lifestyle changes, and emergence of new diseases is also driving interest in biopharmaceuticals.